Efficacy and safety of puerarin injection in curing acute ischemic stroke
A meta-analysis of randomized controlled trials

Qing-Hua Zheng, MM\textsuperscript{a,b}, Xiao Li, BS\textsuperscript{a}, Zhi-Gang Mei, MD\textsuperscript{a,b,\ast}, Li Xiong, PhD\textsuperscript{c}, Qing-Xian Mei, MM\textsuperscript{a,b}, Jin-Feng Wang, MM\textsuperscript{a}, Ling-Jing Tan, MM\textsuperscript{a}, Song-Bai Yang, MD\textsuperscript{a}, Zhi-Tao Feng, MD\textsuperscript{a}

Abstract
Background: Previous studies indicated that the puerarin injection has been widely employed in China for the treatment of acute ischemic stroke. We aim to evaluate the efficacy and safety of the puerarin injection for the treatment of acute ischemic stroke.

Methods: A systematic literature search was performed in PUBLMED, EMBASE, SPRINGER LINK, Scopus, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP Journals Database, Wanfang database and the China Biological Medicine database before November 2016, randomized controlled clinical trials (RCTs) of puerarin injection treating acute ischemic stroke were included. In addition, we searched reference lists of relevant retrieved articles. Two authors extracted data independently. The effective rate, the neurologic deficit score, the blood rheology indexes, and fibrinogen were assessed and analyzed by the Review Manager 5.3 software. The continuous variables were expressed as MD with 95% CI and dichotomous data used RR or ORs. Adverse reactions related to the puerarin injection were also examined.

Results: Thirty-five RCTs with a total of 3224 participants were identified in the meta-analysis. The combined results of 32 trials indicated that the puerarin injection was better than control drugs at the clinical effective rate (RR 1.22, 95% CI 1.17 to 1.28, \( P < 0.001 \)) and 16 studies showed the neurological deficit was significantly improved (MD \(-3.69, 95\% \text{ CI} -4.67\) to \(-2.71, P < 0.001 \)); the hemorheology index and fibrinogen were much lower with the puerarin injection when compared with western conventional medicines (WCM) or other control drugs (the whole blood viscosity: MD \(-0.89, 95\% \text{ CI} -1.37\) to \(-0.41, P < 0.001 \); the HCT: MD \(-0.04, 95\% \text{ CI} -0.06\) to \(-0.02, P < 0.001 \); the fibrinogen: MD \(-0.64, 95\% \text{ CI} -0.96\) to \(-0.31, P < 0.001 \)). Eleven trials reported that the adverse reactions related to the puerarin injection included facial flushing, dizziness, vomiting, nausea, and other mild gastrointestinal discomfort and allergic reaction. No serious adverse drug reactions were reported.

Conclusions: Puerarin injection may be more effective and relatively safe in clinic for treating acute ischemic stroke. However, the current evidence is insufficient due to the poor methodological quality and lack of adequate safety data. Further RCTs are required to examine its efficacy.

Abbreviations: CI = confidence interval, HCT = hematocrit, MCAO = middle cerebral artery occlusion, MD = mean differences, ORs = odds ratios, RCTs = randomized controlled clinical trials, RR = relative risk, WCM = Western conventional medicines.

Keywords: acute cerebral infarction, acute ischemic stroke, meta-analysis, puerarin, randomized controlled trials

Editor: Yung-Hsiang Chen.

Q-HZ and X-LL contributed equally to this study.

Authorship: Z-GM conceived and designed the study; Q-HZ, X-LL, Q-XM, and S-BY collected the data; Q-HZ, X-LL, and LX performed the analysis and prepared the manuscript; F-FW and L-JT made amendments to the manuscript; and Z-TF participated in designing the study and revised the manuscript. All authors read and approved the final version of the manuscript.

Funding: The present study was supported by Open Fund of Key Laboratory of Cardiovascular and Cerebrovascular Diseases Translational Medicine, China Three Gorges University (2016nxg101).

The authors have no conflicts of interest to disclose.

\textsuperscript{a} Third-Grade Pharmacological Laboratory on Chinese Medicine Approved by State Administration of Traditional Chinese Medicine, Medical College of China Three Gorges University, \textsuperscript{b} Yichang Hospital of Traditional Chinese Medicine, Clinical Medical College of Traditional Chinese Medicine, China Three Gorges University, Yichang, Hubei, \textsuperscript{c} Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.

\ast Correspondence: Zhi-Gang Mei and Zhi-Tao Feng, Medical College of China Three Gorges University, Yichang, Hubei 443002, China (e-mails: zhigangmei@139.com [Z-GM]; fengzhitao2008@126.com [Z-TF]).

Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.

Medicine (2017) 96(1e5803)

Received: 25 October 2016 / Received in final form: 6 December 2016 / Accepted: 9 December 2016

http://dx.doi.org/10.1097/MD.0000000000005803
1. Introduction

Stroke is the main cause of death and disability in the world. Although various surveillance systems are used to assess stroke and its sequela, stroke still remains one of the top causes of mortality, disability, and affects the disability-adjusted life years. In China, there are 1.5 to 2 million new cases of stroke each year. Stroke has been ranked as the first leading cause of mortality and long-term disability, which caused a heavy economic burden to the family and even the whole society. The incidence of stroke due to ischemia accounts for 68%. The ischemic stroke is caused by blockages or narrowing of the arteries that provide blood to the brain, resulting in ischemia severely and decreased blood flow. Acute ischemic stroke and metabolic syndrome patients triggered a more intense immune-inflammatory activation, which results in a higher degree of immuno-inflammation and arterial stiffness. Regrettably, so far, no routine effective therapy for ischemic stroke is generally accepted, except for aspirin and thrombolytic treatment with recombinant tissue plasminogen activator for highly selected patients. Therefore, various kinds of complementary and/or alternative medicine are being developed worldwide. Traditional Chinese medicine has been widely used in the treatment of hemorrhage such as rhizoma gastrodiae, radix astragali, radix puerariae, and other Chinese herbal medicine or non-medication therapies for many years.

Gegen, the dried root of pueraria lobata, is one of the earliest and most important edible crude herbs used for various medical purposes in Chinese medicine. Puerarin (relative molecular weight 416.38, Fig. 1), the major bioactive component of the traditional Chinese medicine Radix puerariae (kudzu root), is a major isoflavonoid with polyhydroxy. Puerariae radix has been reported to display anti-inflammatory effects, antiplatelet aggregation, antioxidation, as well as decreasing plasma cholesterol. Puerarin injection was a common dosage form of puerarin for curing microcirculation disturbance and cardio-cerebrovascular diseases as Chinese patent drug for more than 20 years. Randomized controlled trials (RCTs) upon puerarin injection have exhibited to improve neurological deficit after cerebral ischemia in patients. A previous review about puerarin treating ischemic stroke presented a positive conclusion; however, the sample size was too small to draw a reliable conclusion. Therefore, in this paper, we included more trials and aimed to evaluate the clinical efficacy and safety of puerarin injection for treating acute ischemic stroke as well as to provide high-quality evidence for further clinical utilization.

2. Methods

2.1. Database searched

We used “puerarin,” “ischemic stroke,” or “cerebral infarction” as the search terms to search PUBMED, EMBASE, SPRINGER LINK, Scopus, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP Journals Database, Wanfang database, and the China Biological Medicine database before November 2016.

2.2. Inclusion criteria

Ischemic stroke was diagnosed clinically according to the World Health Organization definition or the diagnostic criteria issued at the Second and revised at the Fourth National Cerebrovascular Diseases Conference in China and approved by CT scan or MRI. Patients with ischemic stroke within 7 days of onset and diagnosed without serious organic disease and complications were considered. RCTs that evaluated efficacy and safety of puerarin for ischemic stroke patients were included.

2.3. Intervention measures

The experimental groups were given puerarin with sodium chloride or glucose injection, the intervention for treatment groups included only puerarin herbal without other Chinese medicine. The patients of the control group were given WCM such as aspirin or other medicine without puerarin. In some cases, 2 groups would be given basic treatment on the basis of the condition of the patient in the same time.

2.4. Outcomes

The total effective rate was the primary outcome. Secondary outcomes were the neurological deficit improvement after treatment. Third outcomes included hemorheology index with whole blood viscosity, hematocrit (HCT), and fibrinogen. The adverse events were recorded.

2.5. Data extraction and statistical analysis

For all studies included in the systematic review, data extraction and study quality assessment were independently conducted by 2 authors (Q-HZ and X-LL), with disagreement resolved by consensus. The following data were extracted from each primary study, if available, including study types, patient characteristics, and treatment. The Review Manager 5.3 software was used for data-analysis. A fixed-effect model or random-effect model was used across the trials, and risk ratios with their 95% confidence intervals (CI) were calculated for dichotomous data. If continuous data were available, weighted mean difference or standardized mean difference was to be calculated. I² statistic showed the degree of heterogeneity. Groups were distributed to subgroups based on the different kinds of blood rheology indexes. The bias assessed through the Funnel plot or Egger tests in this study.

2.6. Quality assessment

We evaluated the risk of bias according to the Cochrane risk of bias tool, which included the following 7 domains, random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias.
3. Results

3.1. Assessment of quality

On the basis of search strategy, 523 potentially relevant articles were identified after duplicates removed. Then, 378 articles were excluded by reviewing the types and designs of trials, and another 110 articles were excluded by reviewing the inclusion criteria. Thus, there were 35 primary studies, with 3224 participants in total, included in the systematic review. All of these studies were conducted in China and published before November 2016, described as randomized, and did not report the method of random sequences generation. The study screening procedure was summarized in a flow diagram (Fig. 2). Detailed characteristics of the 35 studies and puerarin dose in each study were described in Table 1. Based on the GRADE system, the evidence of effective rate and neurological deficit score was weak recommendation (Figs. 3 and 4). There was no significant publication bias, and no small study effects were found in the funnel plot (Fig. 5) or revealed by the Egger (P=0.006).

3.2. Outcomes

3.2.1. The clinical effective rate. In total, 32 trials adopted the effective rate to assess the clinical improvement and the

---

Table 1

| Study               | Subjects (trial/control) | Age | Intervention | Control group | Treatment/ADR | ADR |
|---------------------|--------------------------|-----|--------------|---------------|---------------|------|
| Zhang et al, 2006   | 30/30                    | 58.0±11.3 | 57.2±10.8 | Puerarin 500mg, 20% Mannitol | 10 | 2 |
| Jiang, 2006         | 50/50                    | 68.1 | 70.1 | Puerarin 500mg | 14 | 4 |
| Zhou and Lu, 2011   | 40/30                    | 52.3±8.6 | 54.6±8.2 | Puerarin 400mg, Compound Danshen Injection | 14 | None |
| He, 2009            | 50/40                    | 62.0±18.0 | 61.0±21.0 | Puerarin 400mg, Dextran, Compound Danshen Injection | 20 | None |
| Shan et al, 2006    | 82/78                    | 51.2±11.3 | 52.1±10.2 | Puerarin 500mg, WCM | 15 | None |
| Wang and Dong, 2008 | 40/40                    | 55-81 | 50-80 | Puerarin 500mg | 14 | Unclear |
| Wang, 2008          | 73/73                    | 55.9±14.2 | 55.9±14.2 | Puerarin 500mg | 14 | None |
| Tong, 2007          | 26/18                    | 63.0±12.1 | 62.8±10.5 | Puerarin 500mg, WCM | 14 | Unclear |
| Lu and Lu, 2011     | 58/58                    | 72.8±8.9 | 71.2±10.0 | Puerarin 500mg, WCM | 14 | 7 |
| Wang, 2012          | 34/34                    | 57.0±3.6 | 57.4±3.6 | Puerarin 400mg, WCM | 10 | Unclear |
| Zhang, 2010         | 42/57                    | 42-80 | 42-80 | Puerarin 500mg, Compound Danshen Injection | 14 | 1 |
| Xu and Zhou, 2011   | 30/30                    | 43-70 | 42-70 | Puerarin 400mg, Dextran | 14 | Unclear |
| Deng et al, 2007    | 60/60                    | 50-70 | 51-68 | Puerarin 400mg, Dextran, Troxerutin | 28 | None |
| Li, 2008            | 60/60                    | 42-86 | 42-86 | Puerarin 400mg | 14 | Unclear |
| Shi and He, 2006    | 32/32                    | 45-76 | 43-72 | Puerarin 400mg, Ligustrazine | 20 | None |
| Cui and Chen, 2007  | 43/43                    | 43-78 | 45-76 | Puerarin 500mg, WCM | 20 | Unclear |
| Lin, 2006           | 55/55                    | 63.0±12.0 | 61.0±10.5 | Puerarin 400mg, WCM | 15 | None |
| Han, 2009           | 56/54                    | 40-82 | 38-80 | Puerarin 400mg, Dextran, Troxerutin | 15 | None |
| Guo, 2007           | 45/50                    | 43-85 | 45-88 | Puerarin 200mg, Compound Danshen Injection, Dextran, Troxerutin | 14 | 2 |
| Sun, 2010           | 48/36                    | 38-78 | 39-79 | Puerarin 500mg, Compound Danshen Injection, Dextran, Troxerutin | 12 | None |
| Bi et al, 2007      | 50/48                    | 48-79 | 50-77 | Puerarin 400mg, Compound Danshen Injection | 14 | 2 |
| Guo, 2007           | 68/52                    | 42-86 | 40-78 | Puerarin 300mg, Compound Danshen Injection, Misothun | 14 | None |
| Su and Wang, 2007   | 46/45                    | 60.6±2.3 | 60.6±2.3 | Puerarin 400mg, Dextran, Compound Danshen Injection | 14 | None |
| Li, 2013            | 60/50                    | 54.4±19 | 60.2±21 | Puerarin 450mg, Dextran, Troxerutin | 30 | 3 |
| Liu et al, 2010     | 35/35                    | 61.4±10.2 | 60.9±10.25 | Puerarin 600mg, Troxerutin | 20 | Unclear |
| Cai, 2011           | 45/45                    | 42-83 | 45-82 | Puerarin 400mg, Compound Danshen Injection | 28 | None |
| Sun, 2009           | 69/69                    | 55.9±14.2 | 55.9±14.2 | Puerarin 400mg, Compound Danshen Injection | 14 | None |
| Cao, 2010           | 46/46                    | 45-75 | 48-76 | Puerarin 400mg, Compound Danshen Injection | 14 | None |
| Liu and Dong, 2008  | 30/30                    | 46-72 | 48-76 | Puerarin 400mg, Compound Danshen Injection | 14 | None |
| Sun and Li, 2009    | 46/41                    | 50-80 | 48-78 | Puerarin 100–200mg, WCM | 15 | None |
| Deng, 2010          | 51/40                    | 45-80 | 46-79 | Puerarin 300mg, Compound Danshen Injection | 14 | None |
| Zhang and Li, 2001  | 30/20                    | 71.5±5.3 | 71.5±5.3 | Puerarin 400mg, Dextran, Troxerutin | 28 | None |
| Wang, 2003          | 44/43                    | 64.7±9.6 | 65.6±9.3 | Puerarin 400mg, Compound Danshen Injection | 14 | None |
| Wu and Huang, 2001  | 60/48                    | 60.4±6.5 | 61.1±7.1 | Puerarin 400mg, Compound Danshen Injection | 14 | None |
| Wei et al, 2003     | 42/57                    | 64.4 | 69.6 | Puerarin 400mg | 21 | 2 |

ADR=adverse drug reactions, WCM=western conventional medicines.
random-effective model was used for statistical analysis. The analysis showed favor of puerarin (n=2967, RR 1.22, 95% CI 1.17 to 1.28, \( P < 0.001 \)), heterogeneity \( \chi^2 = 58.69, P = 0.002, I^2 = 47\% \), Fig. 6).

3.2.2. The scores of neurological deficits. However, 16 studies which used the neurologic deficit score were qualified to perform a meta-analysis, and the random effective model was used for statistical analysis because of the heterogeneity (\( n = 1358, MD = -3.69, 95\% CI = -4.67 \) to \(-2.71, P < 0.001\), heterogeneity \( \chi^2 = 49.43, P < 0.0001, I^2 = 70\% \)), and favored the puerarin group (Fig. 8).

3.2.3. Blood rheology indexes and fibrinogen. Twelve studies involved whole blood viscosity, and the random effective model was used for statistical analysis because of the heterogeneity (\( n = 1036, MD = -0.89, 95\% CI = -1.37 \) to \(-0.41, P < 0.001, \) heterogeneity \( \chi^2 = 359.22, P < 0.0001, I^2 = 97\% \)) and favored the puerarin group (Fig. 8).

Twelve studies adopted HCT to evaluate the clinical significance of puerarin for the ischemic stroke in hemocyte, due to the heterogeneity (\( n = 1070, MD = -0.04, 95\% CI = -0.06 \) to \(-0.02, P < 0.001, \) heterogeneity \( \chi^2 = 243.98, P < 0.0001, I^2 = 96\% \)), the random effective model was used. The consequence showed the favor of experimental group (Fig. 9).

Eleven of the studies adopted the fibrinogen to assess the clinical improvement and the random-effective model was used for statistical analysis (heterogeneity \( \chi^2 = 233.64, P < 0.0001, \) \( I^2 = 96\% \)). The puerarin group was significantly lower than the fibrinogen control group (\( n = 1011, MD = -0.64, 95\% CI = -0.96 \) to \(-0.31, P < 0.001 \)) (Fig. 10).

3.3. Safety
Due to the variety of symptoms and the low number of adverse reactions reported, it was difficult to conduct a meta-analysis, so the adverse reactions were described. Eleven studies reported that patients might be temporary bloating, nausea and other gastrointestinal reactions, dizziness and facial flushing, but the symptoms were relieved after continued treatment. \[19,20,27,30,37,39,42,46,49,50,53\] rashes was reported in 2 trials, \[37,49\] whereas the left trials reported no adverse effects. No serious adverse drug reactions occurred.

4. Discussion
In our study, the efficacy and safety of puerarin injection in curing acute ischemic stroke were investigated. Thirty-five RCTs involving a total of 3224 participants with acute ischemic stroke were included. The results demonstrated that puerarin could improve the neurological deficit of acute ischemic stroke, lower blood viscosity, and reduce fibrinogen production. The outcomes were partially similar to the results of a previous review, \[13\] which just assessed the efficiency of puerarin for ischemic stroke and showed that puerarin improved neurological deficit significantly more than the control. However, the review neither evaluated the effect on blood rheology indexes nor fibrinogen, and its possible mechanism was not discussed. Actually, plasma fibrinogen played a major determinant in platelet aggregation and blood viscosity, whereas high blood viscosity led to blood stagnation and then promoted thrombosis, resulting in the development of ischemic stroke. \[54,55\] So evaluating the effect of puerarin injection on blood rheology indexes and fibrinogen was important. Moreover, our enrolled sample size was much larger and we focused on acute ischemic stroke treatment, whereas they included acute and chronic ischemic stroke. In summary, our study tried to offer a high-quality evidence-based approach upon puerarin injection for treating ischemic stroke.

As we all know, the ischemic stroke is a common cardiovascular disease involves death of brain tissue (cerebral infarction) resulting from an inadequate supply of blood and oxygen to the brain due to blockage of an artery. \[16\] Ischemic stroke causes a lot of damage to body and seriously affects the quality of life. Because the high morbidity and mortality of acute ischemic stroke patients increased with increasing age, which threatens the health of human beings. \[57\] Hypoxic ischemic brain injury often causes irreversible brain damage and the cascade of events leading to neuronal injury and death in ischemia includes the release of cytokines and free radicals, and induction of inflammation, apoptosis, and excitotoxicity. \[58\] Many pharmacological interventions such as thrombolytic, antioxidant, cerebral vasodilator, Ca\(^{2+}\) channel blocker, and free
radical scavenger have been observed to produce acute ischemia and cerebral ischemia-reperfusion protection.[7] Insufficiently, the usage criteria and administration time window are limited in thrombolytic,[59] and cerebral hemorrhagic complications occur more easily.[60] Therefore, it is necessary to seek some new alternative medicine with the characteristics of high safety, high efficiency, and synthetic therapeutic effects. In China, multiple kinds of Chinese medicinal herbs or effective constituents, such as Buyang Huanwu decoction,[6] compound salvia injection,[61] Xuesetong injection,[62] and puerarin injection we discussed here, have been widely used to treat ischemic stroke for a long history. Puerarin is a major isoflavonoid derived from the Chinese medical herb radix puerariae (Gegen), which is the root of the familiar kudzu vine. In traditional Chinese medicine, radix puerariae has been widely used in the treatment of cerebrovascular disorders, cardiovascular diseases, cancer, Alzheimer’s disease (AD), and diabetes and diabetic complications.[63]

Puerarin is an isoflavone compound separated from the drying of kudzu root and its injection was purified and developed from the 1990s of the 20th century.[13] By reviewing the recent pharmacological researches, we found that puerarin was a potent neuroprotective drug on MCAO-induced focal cerebral ischemia in vivo, by inhibiting both HIF-1α and TNF-α activation, followed by the inhibition of inflammatory responses (i.e., iNOS expression), apoptosis formation (active caspase-3), and neutrophil activation, resulting in a reduction of infarct volume in ischemia reperfusion brain injury.[64] Also, Liu et al[65] reported that puerarin reduced the ischemic infarct volume and improved neurological deficit after cerebra ischemia/reperfusion by activating the cholinergic anti-inflammatory pathway. In our meta-analysis, the neurologic deficit score of puerarin injection group did improve when compared with the control group (MD –3.69, 95% CI –4.67 to –2.71, P < 0.001). Yan et al[66] indicated that puerarin was relevant to triggering extracellular Ca2+ influx into endothelial cytosol, which involved the endothelial Ca2+-NO–cGMP pathway, prostacyclin, and opening of the 3 K+ channels and then effected the endothelium-dependent antivasoconstrictive; Pan et al[10] suggested that the puerarin injection could ameliorate the hemorheology and the abnormal augmentation of platelet aggregation, which these pharmacological researches met with the results of our meta-analysis that puerarin injection could reduce blood viscosity.

There are still some limitations in our study. For example, the period of most observation lasted for only 14 days and none of studies reported the record of results and dropout data, long-term observation, and following-up are required in further study. And there are several methodological limitations in the primary studies; all trials were RCTs but none of them reported...
the random method or allocation concealment, which may produce selection bias. So that, more randomized, double-blind, controlled, multicenter of clinical trials are needed. Though we made effort to find more clinical experiment trails, all the studies were from China mainland. All the adverse reactions were described due to only a few of the included trials reported adverse events and the cases, which was not enough for statistical analysis. In addition, the dose of included trials was different,
which varied from 0.2 g to 0.6 g, and no standard dose delivered to the acute ischemic stroke target was obtained.

In conclusion, the meta-analysis indicates that the puerarin injection is more effective than WCM and provides evidence-based approach for treating ischemic stroke. However, more high quality-RCTs are needed to provide reliable evidence on the effectiveness of puerarin injection for treating acute ischemic stroke.
References

[1] Mkhurlage D, Patil CG. Epidemiology and the global burden of stroke. World Neurosurg 2011;76:585–90.

[2] Zhang X, Sun Z, Ding C, et al. Metabolic syndrome augments the risk of early neurological deterioration in acute ischemic stroke patients independent of inflammatory mediators: a hospital-based prospective study. Oxid Med Cell Longev 2016;2016:1–6.

[3] Krishnamurthy RV, Feigin VL, Forouzanfar MH, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health 2013;1:e259–81.

[4] Dirmagl U, Iadeola C, Moskwitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999;22:391–7.

[5] Tuttolomondo A, Pecoraro R, Di RD, et al. Inflammatory markers and arterial stiffness indexes in subjects with acute ischaemic stroke with and without metabolic syndrome. Diabetol Metab Syndr 2014;6:28.

[6] Wu B, Liu M, Liu H, et al. Meta-analysis of traditional Chinese patent medicine for ischemic stroke. Stroke 2007;38:1973–9.

[7] Hao C, Wu F, Shen J, et al. Clinical efficacy and safety of buyang huanwu decoction for acute ischemic stroke: a systematic review and meta-analysis of 19 randomized controlled trials. Evid Based Compl Alternat Med 2012;2012:630124.

[8] Pan HP, Li G. Protecting mechanism of puerarin on the brain neurocyte of rat in acute local ischemia brain injury and local cerebral ischemia-reperfusion injury. Yakugaku Zassi 2008;128:1689–98.

[9] Lim DW, Lee C, Kim IH, et al. Anti-inflammatory effects of total isoflavones from pueraria lobata on cerebral ischemia in rats. Molecules 2013;18:10404–12.

[10] Han J, Wang LS, et al. The observation of efficacy of puerarin with acute cerebral infarction (Chinese). J Emerg Trad Chin Med 2006;12:1335–51.

[11] Cui Q, Chen YP. Clinical analysis of puerarin for cerebral infarction (Chinese). Asia-Pacific Trad Chin Med 2007;6:26–7.

[12] Shi GY, Shi Y, et al. The research of puerarin injection with acute cerebral infarction (Chinese). J Emerg Trad Chin Med 2007;8:310–1.

[13] Liu Y, Han Y. The study of clinical efficacy of puerarin with acute cerebral infarction (Chinese). China J Chin Mater Med 2007;32:2370–3.

[14] Sun JS. The observation of efficacy of puerarin injection with acute cerebral infarction (Chinese). Public Med Forum Magazine 2007;8:310–1.

[15] Zhou ZJ, Guo ZQ, et al. The observation of clinical efficacy of puerarin with acute cerebral infarction (Chinese). Acta Academiae Medicinae Sinicae 1996;1:59.

[16] Cui Q, Chen YP, et al. Clinical observation of puerarin injection with acute cerebral infarction (Chinese). Clin J Trad Chin Med 2007;3:117–8.

[17] Su YH, Wang XL. The observation of efficacy of puerarin injection with acute cerebral infarction (Chinese). Mod J Integr Trad Chin West Med 2008;9:66–7.

[18] Wang FS. The observation of efficacy of puerarin in 46 cases with acute cerebral infarction (Chinese). Mod J Integr Trad Chin West Med 2007;5:612–3.

[19] Lu JM, Lu YZ. The observation of efficacy of puerarin in 58 cases with acute cerebral infarction (Chinese). Chin J Gerontol 2011;11:2575–6.

[20] Wang YC. The study of clinical efficacy of puerarin in 68 cases with acute cerebral infarction (Chinese). Med Rev 2012;31:1774–6.

[21] Zhang AJ. To observe 79 cases clinical curative effects of the puerarin to treat acute cerebral infarction (Chinese). Chin Med Mod Dist Educ China 2010;24:33.

[22] Xu P, Zhou YF. The observation of efficacy of puerarin with acute cerebral infarction (Chinese). China J Clin Rational Drug Use 2011;20:58–9.

[23] Deng SQ, Zheng QP, Li JM. The observation of clinical efficacy of puerarin with acute cerebral infarction (Chinese). Appl J Gen Pract 2007;4:345.

[24] Li YG. Clinical study of puerarin for cerebral infarction (Chinese). Chin J Mod Drug App 2008;23:87–8.

[25] Shi SH, He CY. The observation of efficacy of puerarin with acute cerebral infarction (Chinese). J Emerg Trad Chin Med 2006;12:1335–51.

[26] Li YP, Zhang RH, et al. Analysis of puerarin injection for cerebral ischemia-reperfusion injury and local cerebral ischemia (Chinese). Natl Med J Chin 2006;7:29–30.

[27] Chen Q, Chen YP. Clinical analysis of puerarin for cerebral infarction (Chinese). Acta Academiae Medicinae Sinicae 1996;1:59.

[28] Li YP, Zhang RH, et al. Analysis of puerarin injection for cerebral ischemia-reperfusion injury and local cerebral ischemia (Chinese). Natl Med J Chin 2006;7:29–30.
[56] Emsley HCA, Smith CJ, Tyrrell PJ, et al. Inflammation in acute ischemic stroke and its relevance to stroke critical care. Neurocrit Care 2008;9:125–38.
[57] Wang H, Ren S, Liu C, et al. An overview of systematic reviews of danhong injection for ischemic stroke. Evid-Based Comp Alt 2016;2016:894983; doi: 10.1155/2016/894983.
[58] Liu Z, Li P, Dan Z, et al. Protective effect of extract of Cordyceps sinensis in middle cerebral artery occlusion-induced focal cerebral ischemia in rats. Behav Brain Funct 2010;6:61.
[59] Hajjar K, Kerr DM, Lees KR. Thrombolysis for acute ischemic stroke. Geriatrics 2011;54:901–7.
[60] Masingue M, Alamowitch S. An update on limitations of intravenous thrombolysis to treat acute ischemic stroke. Presse Med 2015;44:515–25.
[61] Zhang RJ, You C, Cai BW. Effect of compound salvia injection on blood coagulation in patients with traumatic cerebral infarction (Chinese). Chin J Integr Trad West Med 2004;24:882–4.
[62] Zhang X, Wu J, Zhang B. Xuesaitong injection as one adjuvant treatment of acute cerebral infarction: a systematic review and meta-analysis. BMC Complement Altern Med 2015;15:1–0.
[63] Zhou YX, Zhang H, Peng C. Puerarin: a review of pharmacological effects. Phytother Res 2014;28:961–75.
[64] Yi C, Hsieh CY, Peng ZA, et al. Neuroprotective mechanisms of puerarin in middle cerebral artery occlusion-induced brain infarction in rats. J Biosoc Sci 2009;16:1–3.
[65] Liu XJ, Mei ZG, Qian JP, et al. Puerarin partly counteracts the inflammatory response after cerebral ischemia/reperfusion via activating the cholinergic anti-inflammatory pathway. Neural Regen Res 2013;8:3203–15.
[66] Yan LP, Zhuang YL, Chan SW, et al. Analysis of the mechanisms underlying the endothelium-dependent antivasoconstriction of puerarin in rat aorta. Naunyn Schmiedebergs Arch Pharmacol 2009;379:587–97.